<DOC>
	<DOC>NCT02272634</DOC>
	<brief_summary>This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily [BID]) and a placebo control in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.</brief_summary>
	<brief_title>A Phase 2a Study to Assess Safety, Daily Symptoms, Pharmacokinetics (PK), and Biomarkers of YPL-001 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Adult males and/or females, 40 to 80 years of age (inclusive). History of COPD for at least 12 months prior to screening. Diagnosed with COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD for at least 12 months prior to screening. Classified as moderate to severe COPD based on the current severity classification GOLD Stage 23 disease in terms of postbronchodilator spirometry at screening etc. History of lifethreatening COPD including respiratory arrest, intensive care unit admission and/or requiring intubation. History of more than 2 hospitalizations for COPD within 12 months prior to screening. Presentation of an acute exacerbation of COPD that will be associated with increase sputum volume or change in sputum color within 4 weeks before Day 1 of the Runin Period. Evidence of pulmonary heart disease, or clinically significant pulmonary hypertension. etc.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>